When does venture debt preserve a medtech company’s independence?

Venture debt can preserve a medtech company’s strategic independence when it funds a credible milestone before repayment pressure forces the next transaction. Lower immediate dilution does not necessarily mean greater freedom. Drawdown conditions, debt service, minimum liquidity and commercial dependencies can restrict decisions even when founders retain their voting rights and the product continues to develop.

Clinical milestones and usable financing

Medtech companies commonly face several different timelines. Clinical evidence develops at one pace; regulatory assessment, manufacturing readiness and customer adoption follow their own schedules. Funding needs continue between them. A successful technical milestone may improve the next financing opportunity without generating operating cash. Debt is therefore best assessed against the complete route to a financeable business, including a plausible delay, rather than against the date of the next study result alone.

The European Investment Bank describes venture debt as complementary to equity finance and looks for an established business plan, professional equity backing and appropriate governance. Its availability should not be interpreted as evidence that a company has already become self-financing. The assessment remains company-specific. A lender can accept development risk while still requiring the borrower to raise further equity or meet conditions before accessing every part of a facility.

A financing announcement also needs to be translated into usable cash. Median Technologies’ July 2025 announcement described an EIB agreement for up to €37.5 million. A facility ceiling is not the amount immediately available for product development. Tranches, conditions, fees and any repayment of existing obligations determine the incremental cash.

Repayment, dilution and liquidity constraints

Consider an illustrative €6 million loan whose principal must be repaid evenly over three years after a grace period. Annual principal repayment is €2 million before interest. At a 60% cash contribution margin, approximately €3.33 million in additional annual revenue would be required to cover principal alone, before fixed operating costs, investment and tax. This does not imply that a lender requires repayment solely from product revenue. It reveals how dependent the financing plan remains on later equity, refinancing or a transaction if operating cash cannot meet that burden.

The cost of debt can extend beyond the interest rate. Warrants or conversion features may add dilution, while liquidity requirements can limit spending before the contractual maturity date. A borrower should compare the cash available and strategic options under both a successful programme and a delayed one. An apparently cheaper loan can become expensive if it compels a licensing deal at a weak negotiating point. Conversely, equity raised early can be costly if a near-term milestone could credibly improve terms without exposing the enterprise to a severe funding gap.

Market access and strategic independence

A regulatory milestone and a commercial milestone should not be treated as interchangeable. Permission to market a device does not itself demonstrate that hospitals will procure it, reimbursement will support its price or clinicians will adopt the associated workflow. Establishing distribution, training, service and evidence relevant to purchasing decisions can require substantial capital. A financing model that stops at authorisation understates the distance to recurring receipts. The required commercial investment depends on the device, territory and customer, and needs specialist assessment where regulatory or reimbursement assumptions are material.

A distribution partnership can fund or accelerate market access, but it transfers another form of control. Exclusive rights, minimum commitments, pricing authority and ownership of customer relationships may constrain the manufacturer long after a loan is repaid. Those commitments can be worthwhile if the partner supplies capabilities the company cannot reproduce economically. The comparison with debt and equity should therefore include who can decide the next product, territory or channel strategy, and what happens if the partner does not invest as expected.

Independence is valuable when it gives management useful choices, not simply a higher ownership percentage. A sustainable financing structure provides enough cash to reach a milestone whose value can be realised, while leaving alternatives if timing or adoption disappoints. For founders and advisers, the decisive evidence is the relationship between cash availability, obligation dates and the capabilities still to be financed. Debt can strengthen that position, but only if the business can carry the commitments it creates.